Is Regeneron Stock a Bargain Below $800?
Regeneron Pharmaceuticals ' (NASDAQ: REGN) shares climbed well above $1,000 two years ago, reaching all-time highs. However, they have dropped significantly from those levels over the past 24 months and now sit slightly below $800 apiece. What has happened to Regeneron? Is the stock a great buy at current levels? Let's find out. In the second quarter, Regeneron's revenue increased by 17% year over year to $4.3 billion. That was a strong performance for the biotech, largely driven by its biggest growth driver, Dupixent, a medicine it co-markets with Sanofi (NASDAQ: SNY) . Dupixent's global net sales (recorded by Sanofi) jumped 38% year over year to $6 billion. Image source: The Motley Fool. Continue reading